Elite Health pivots to Medicare Advantage; zero revenue, conditional CMS approval, fundraising

Elite Health Systems Inc. (OTCMKTS: USNU) - Quick internal update

Short take: the company is pivoting to operate Medicare Advantage plans (Elite Health). It has no revenue yet, is investing in platform and licensing, has raised equity but continues to lose money and faces going-concern risk. Management points to recent private financings and conditional regulatory approvals as the path forward.

Key facts & statistics

* Cash and cash equivalents (June 30, 2025): $3,121,000

* Total assets: $3,984,000 (Dec 31, 2024: $4,321,000)

* Total liabilities: $197,000 (Dec 31, 2024: $143,000)

* Stockholders' equity: $3,787,000 (Dec 31, 2024: $4,178,000)

* Accumulated deficit: ($5,310,000) (Dec 31, 2024: ($4,445,000))

* Three months ended June 30, 2025 - Revenue: $0; Net loss: ($441,000) vs ($435,000) in Q2 2024

* Six months ended June 30, 2025 - Revenue: $0; Net loss: ($865,000) vs ($747,000) in H1 2024

* SG&A, Q2 2025: $445,000 (Q2 2024: $437,000); SG&A, H1 2025: $872,000 (H1 2024: $913,000)

* Basic & diluted loss per share, Q2 2025: ($0.02) (Q2 2024: ($0.03)) - weighted avg shares Q2 2025: 21,409,924

* Capitalized software under development: $767,000 (June 30, 2025)

* Net cash used in operating activities (six months ended June 30, 2025): ($631,000); Net change in cash: ($913,000)

* Raised gross proceeds through private placements: ~$5.8 million (through June 30, 2025); subsequent July 2025 private placement planned: minimum $2,000,000 up to $5,000,000 at $0.95/share

Positive aspects (income statement & corporate)

* Operating costs are predictable and concentrated in SG&A - management reduced H1 SG&A to $872,000 from $913,000 year-over-year.

* Company has funded operations via equity - ~$5.8M raised and more planned; cash balance of $3.1M provides runway near-term.

* Active investment in internal technology: $767,000 capitalized software - shows build-out of platform for Medicare Advantage operations.

* Regulatory progress: Knox‑Keene license awarded (May 2025) and conditional CMS approval for CY2026 MA application - essential green lights for revenue generation.

Negative aspects (income statement & risks)

* Zero revenue - losses entirely financing start-up activity: Q2 loss ($441,000); H1 loss ($865,000).

* Growing accumulated deficit: ($5.31M) and continuing cash burn (net change in cash H1: ($913,000)).

* Dilution: shares outstanding rose to 21,409,924 (issuances and private placements); further dilution likely given planned raises and proposed share-based acquisition.

* Going-concern disclosure: substantial doubt noted at June 30, 2025 - company depends on further capital raises and regulatory milestones.

* Related-party risk: July 2025 non-binding LOI to acquire Physician Support Systems (PSS) in exchange for 3,158,000 shares; CEO/insiders have material ownership in PSS - potential conflict and dilution.

What's happening inside - catalysts, near-term actions and internal issues

* Operating focus: building Elite Health (Medicare Advantage plans) for CA (San Bernardino, Riverside, LA) and expansion plans for Nevada.

* Regulatory catalysts: Knox‑Keene license obtained; conditional CMS approval received for CY2026 - final CMS approval and subscriber enrollment are the next revenue triggers.

* Financing plan: private placement July 2025 (min $2M / max $5M at $0.95/share); a $2.5M line of credit exists (undrawn) to meet tangible net worth requirements for licensure.

* M&A move: LOI to acquire PSS (related party) for stock - would expand operations but increases insider-related transaction risk and dilution.

* Internal control: management identified a prior material weakness in accounting resources; they engaged a consultant and believe it has been remediated.

Bottom line

Elite Health Systems (OTCMKTS: USNU) is a development-stage health‑plan operator with promising regulatory progress but no revenue yet. The company has runway from equity raises and an undrawn LOC, is investing in software and licensing, but still posts recurring losses, rising accumulated deficit and faces meaningful execution, financing and related‑party risks. Key near-term items to watch: final CMS approval, successful private placement ($2M-$5M), and any definitive deal terms for the PSS acquisition.